ストックスクリーナーアプリを入手
2.91
0.00%
0.00
アフターアワーズ：
2.92
0.010
+0.34%
Esperion Therapeutics Inc (ESPR) 最新ニュース
electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - TradingView
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Yahoo Finance UK
Esperion to acquire Corstasis for cardiovascular franchise expansion - Pharmaceutical Technology
Esperion Therapeutics: $75 Million Acquisition Of Corstasis To Expand Cardiovascular Franchise With Enbumyst Nasal Spray - Pulse 2.0
Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 13.1%Should You Sell? - MarketBeat
Ann Arbor pharmaceutical company to pay $75M in deal for new drug - Crain's Detroit Business
Esperion Therapeutics (NASDAQ:ESPR) Given New $5.00 Price Target at Needham & Company LLC - MarketBeat
Esperion to acquire Corstasis Therapeutics - The Pharma Letter
Esperion Acquires Enbumyst Maker Corstasis - Bitget
Esperion Acquires Enbumyst Maker Corstasis - Benzinga
Esperion to Acquire Corstasis, Expanding Heart Failure Portfolio - TipRanks
Esperion Therapeutics to Acquire Corstasis for $75 Million Upfront, Plus Up to $180 Million Milestones - TradingView
Esperion (NASDAQ: ESPR) adds Enbumyst CHF drug in Corstasis acquisition - Stock Titan
Esperion Therapeutics to Acquire Corstasis for $75 Million in Cash - marketscreener.com
Esperion Therapeutics to acquire Corstasis Therapeutics, expands cardiovascular portfolio with Enbumyst nasal spray - Traders Union
Esperion to acquire Enbumyst maker for $75M plus milestones - Investing.com
ESPR: Acquisition brings a novel FDA-approved nasal spray diuretic, expanding cardiovascular offerings - TradingView
Esperion Therapeutics and Corstasis Therapeutics Announce - GlobeNewswire
ESPR Should I Buy - Intellectia AI
ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Esperion Therapeutics Inc devrait afficher une perte de 13 cents par actionEarnings AVANT-PAPIER - TradingView
Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy? - Finviz
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10 - The Manila Times
Cholesterol drug biopharma Esperion sets March 10 results webcast - Stock Titan
Esperion Therapeutics (ESPR) to Release Earnings on Tuesday - MarketBeat
How Esperion Therapeutics Inc. stock benefits from tech adoption2025 Biggest Moves & Technical Entry and Exit Tips - mfd.ru
Why is Esperion Therapeutics Inc. stock going upJuly 2025 EndofMonth & Free Community Consensus Stock Picks - mfd.ru
Aug Setups: Can Esperion Therapeutics Inc outperform under higher oil pricesQuarterly Risk Review & Capital Efficient Trading Techniques - baoquankhu1.vn
Esperion to Participate in The 2026 Citizens Life Sciences Conference - Bitget
Esperion settles another lawsuit to keep generic versions of popular drug off shelves - Cardiovascular Business
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL and NEXLIZET Prior to April 19, 2040 - marketscreener.com
How to listen to Esperion at the 2026 Citizens Life Sciences event - Stock Titan
Setup Watch: What is the next catalyst for Esperion Therapeutics IncWeekly Risk Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Esperion Therapeutics: Past The Turnaround, Waiting On Guidelines (NASDAQ:ESPR) - Seeking Alpha
Esperion Therapeutics (ESPR) has signed a settlement agreement with a fifth generic drug applicant. - Bitget
Esperion settles patent dispute with Alkem over cholesterol drugs - Investing.com
Esperion and Alkem Laboratories Settle Patent Litigation Over NEXLETOL and NEXLIZET - Quiver Quantitative
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040 - Bitget
Esperion Reaches Settlement Agreement with Fifth ANDA Filer - GlobeNewswire
Aug Volume: Is Esperion Therapeutics Inc. still a buy after recent gains2025 Key Highlights & Free Community Consensus Stock Picks - mfd.ru
Gibson Energy Inc. (OTCMKTS:GBNXF) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
What’s the fair value of Esperion Therapeutics Inc. stockAnalyst Upgrade & Low Risk High Reward Ideas - mfd.ru
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by Wall Street Zen to "Hold" - MarketBeat
What is the next catalyst for Esperion Therapeutics Inc.Stock Surge & Weekly Return Optimization Plans - mfd.ru
Is Esperion Therapeutics Inc. in a bullish channelJuly 2025 Price Swings & Weekly Chart Analysis and Trade Guides - mfd.ru
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Market Trends: How does Esperion Therapeutics Inc. score in quality rankings2025 Key Highlights & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
What is the next catalyst for Esperion Therapeutics IncWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Weekly Trades: How does Esperion Therapeutics Inc. score in quality rankingsMarket Risk Report & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Zacks Research Issues Optimistic Forecast for ESPR Earnings - MarketBeat
Zacks Research Analysts Reduce Earnings Estimates for ESPR - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Raised to "Buy" at Wall Street Zen - MarketBeat
0.21%
1.77%
大文字化:
|
ボリューム (24 時間):